Stifel raised the firm’s price target on Sight Sciences (SGHT) to $8 from $6 and keeps a Buy rating on the shares. The firm’s survey of 37 optometrists and ophthalmologists who use Sight’s TearCare came back positive and physician satisfaction is high, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences, Inc. (SGHT) Q4 Earnings Cheat Sheet
- Sight Sciences Extends Menlo Park Headquarters Lease Agreement
- Sight Sciences resumed with an Outperform at William Blair
- Midday Fly By: JPMorgan reports mixed Q4, L3Harris to form new missile company
- Sight Sciences reports preliminary Q4 revenue $20.3M-$20.4M, consensus $20.17M